Cite
A Phase 4, Open-Label, Single-Arm Study Assessing the Efficacy and Safety of Ivabradine in African American Patients with Heart Failure and Reduced Ejection Fraction.
MLA
Lanfear, David E., et al. “A Phase 4, Open-Label, Single-Arm Study Assessing the Efficacy and Safety of Ivabradine in African American Patients with Heart Failure and Reduced Ejection Fraction.” Cardiology & Therapy, vol. 9, no. 2, Dec. 2020, pp. 561–68. EBSCOhost, https://doi.org/10.1007/s40119-020-00196-1.
APA
Lanfear, D. E., Neaton, K. R., Lu, C., Liu, Y., & Dent-Acosta, R. E. (2020). A Phase 4, Open-Label, Single-Arm Study Assessing the Efficacy and Safety of Ivabradine in African American Patients with Heart Failure and Reduced Ejection Fraction. Cardiology & Therapy, 9(2), 561–568. https://doi.org/10.1007/s40119-020-00196-1
Chicago
Lanfear, David E., Kelsey R. Neaton, Chen Lu, Yimeng Liu, and Ricardo E. Dent-Acosta. 2020. “A Phase 4, Open-Label, Single-Arm Study Assessing the Efficacy and Safety of Ivabradine in African American Patients with Heart Failure and Reduced Ejection Fraction.” Cardiology & Therapy 9 (2): 561–68. doi:10.1007/s40119-020-00196-1.